ACP-105

ACP-105 is a synthetic, nonsteroidal selective androgen receptor modulator (SARM). Chemically it is 2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile, built around an azabicyclic tropanol core rather than the four-ring steroid skeleton of testosterone ^[1][3]. It was discovered and developed by ACADIA Pharmaceuticals using a receptor screening technology, and reported in 2009 as a novel, potent SARM that behaves as a partial agonist at the androgen receptor relative to the natural hormone testosterone ^[1].

Like other SARMs, ACP-105 was pursued because it aims to separate the desirable anabolic actions of androgens on muscle and bone from their less desirable effects on other tissues, a property described as tissue selectivity ^[4]. In its original preclinical characterization, oral ACP-105 improved anabolic parameters in castrated male rats over a two-week course, supporting its potential in areas such as muscle wasting, osteoporosis, and androgen-replacement therapy ^[1]. Beyond muscle and bone, it has been studied for effects on the brain; in female mice, ACP-105 enhanced learning in a fear-conditioning task and protected sensorimotor function against radiation-induced impairment, pointing to possible neuroprotective and cognitive applications ^[2].

Despite this promise, ACP-105 has never received clinical approval, and much of the published literature comes from anti-doping science rather than therapeutic trials. SARMs as a class have been prohibited in sport by the World Anti-Doping Agency since 2008, and researchers have characterized ACP-105 and its many hydroxylated metabolites specifically to enable its detection in human and equine doping control samples ^[3][4][5]. Its human safety profile remains insufficiently explored and has so far been assessed mainly through in silico toxicity prediction rather than clinical study ^[6]. It circulates as a research chemical, typically as a powder or in capsule or liquid form, and is not an approved drug or dietary supplement.

Every bit of the human picture here is a blank; ACP-105 never reached human clinical trials, so there is no established safety profile, no characterized half-life, and no dosing anyone can point to with confidence. Judging by the SARM class it belongs to, the expected cautions are suppression of your natural testosterone, unfavorable lipid shifts (HDL tends to drop), and possible liver strain, so bloodwork and a proper recovery protocol are the sensible baseline if someone experiments. Source purity is a real concern too, since research-chemical SARMs are frequently underdosed or contaminated. It is investigational and not approved for human use anywhere, and it is banned in competitive sport. Treat it as research only.

ACP-105 is a nonsteroidal selective androgen receptor modulator that originated in pharmaceutical research on tissue-selective androgens, developed as a partial agonist intended to capture the anabolic benefits of androgens with greater selectivity than testosterone. Its early preclinical characterization used the classic castrated-rat model to demonstrate androgenic activity after oral dosing.

Interest widened when it was studied in the brain; in a mouse model of Alzheimer's disease, ACP-105 reduced anxiety-like behavior and, combined with a selective estrogen receptor beta agonist, lowered amyloid-beta levels and improved cognition, hinting at a role for androgen signaling in neuroprotection. Because it is extensively metabolized and detectable in urine for days, it has also become a well-studied analyte in sports doping control. Its safety and toxicity in humans have not been established in clinical studies.

ACP-105 has a standout reputation among research-grade SARMs, prized both for its anabolic potency and for an unusually intriguing secondary story in the brain. Physique-focused users are drawn to the promise of muscle- and bone-building action with the tissue selectivity that defines the SARM class, while the neuroprotective and cognitive signals seen in animal work give it an extra layer of scientific interest that few of its peers share. The responsible framing, which serious discussions include, is that all of this rests on preclinical and doping-control research; there are no human clinical safety data, and its risk profile has so far been approached mainly through computational prediction. It is best treated as a genuinely interesting but still experimental compound.